表紙
市場調査レポート

PharmaPoint:過敏性腸症候群 (IBS) - 日本の医薬品市場の2023年までの予測と市場分析

PharmaPoint: Irritable Bowel Syndrome - Japan Drug Forecast and Market Analysis to 2023

発行 GlobalData 商品コード 325951
出版日 ページ情報 英文 107 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.69円で換算しております。
Back to Top
PharmaPoint:過敏性腸症候群 (IBS) - 日本の医薬品市場の2023年までの予測と市場分析 PharmaPoint: Irritable Bowel Syndrome - Japan Drug Forecast and Market Analysis to 2023
出版日: 2014年12月31日 ページ情報: 英文 107 Pages
概要

過敏性腸症候群 (IBS) は、よく見られる障害で、腸機能の変化に関係して、腹部の不快感を特徴としています。IBSは、生死に関わる病気ではありませんが、患者の生活の質 (QOL) にかなりの影響を与えます。

当レポートでは、日本の過敏性腸症候群 (IBS) の治療薬市場について調査分析し、疾患の概要とガイドライン、競合情勢、主要薬剤の詳細情報 (製品説明、安全性、有効性) 、SWOT分析、売上高予測、影響分析 (動向、促進要因・抑制要因) などについて、体系的な情報を提供しています。

第1章 目次

第2章 イントロダクション

第3章 疾患の概要

  • 病因・病態生理
  • 分類
  • 症状
  • 予後
  • 生活の質 (QOL)

第4章 疾患の管理

  • 診断と治療の概要
  • 日本

第5章 競合評価

  • 概要
  • 製品プロファイル:主要ブランド
  • その他の薬効分類

第6章 アンメットニーズと機会

  • 概要
  • より効果的な薬物療法
  • IBS Dタイプの治療法
  • IBS Mタイプの治療法
  • 腹痛と膨満感の症状に対処する治療法
  • IBSの診断率の向上

第7章 パイプライン評価

  • 概要
  • 臨床開発中の有望な薬剤
  • 製品プロファイル:後期パイプライン (IBS D)
  • 製品プロファイル:後期パイプライン (IBS C)
  • その他

第8章 市場の見通し

  • 日本

第9章 付録

図表

目次
Product Code: GDHC272CFR

Irritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with altered bowel function. Although IBS is not a life-threatening disorder, it has a considerable effect on patients' quality of life (QOL). In terms of volume, the IBS market is a large, albeit naive, one, with only a small number of pharmacotherapies indicated for the treatment of the disorder, and it is also characterized by significant unmet needs.

The key growth drivers for the IBS market in Japan are the anticipated label expansion of Astellas' Irribow for the treatment of women with IBS-D, and the potential introduction of five additional therapies for IBS during the forecast period. Antidepressants represented the remaining 32% of the market. The anticipated label expansion of Irribow for treating women with IBS-D, and the potential introduction of five new therapies for IBS, is set to change the IBS market dynamics in Japan.

Scope

  • Overview of Irritable Bowel Syndrome including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in the Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in the Japan from 2013-2023.
  • Analysis of the impact of key events as well the drivers and restraints affecting the Japan Irritable Bowel Syndrome.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Irritable Bowel Syndrome
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2013-2023 in the Japan

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Classification
  • 3.3. Symptoms
  • 3.4. Prognosis
  • 3.5. Quality of Life

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Diagnosis
    • 4.1.2. Treatment Guidelines and Leading Prescribed Drugs
    • 4.1.3. Clinical Practice
  • 4.2. Japan

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Product Profiles - Major Brands, IBS-C
    • 5.2.1. Amitiza (lubiprostone)
    • 5.2.2. Linzess (linaclotide)
  • 5.3. Product Profiles - Major Brands, IBS-D
    • 5.3.1. Irribow (ramosetron)
  • 5.4. Product Profiles - Major Brands, Other
    • 5.4.1. Antidepressants
  • 5.5. Other Therapeutic Classes

6. Unmet Need and Opportunity

  • 6.1. Overview
  • 6.2. More Effective Pharmacotherapies
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Therapies for the IBS-D Subtype
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Therapies for the IBS-M Subtype
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Therapies to Address Abdominal Pain and Bloating Symptoms
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity
  • 6.6. Improved Diagnosis Rate for IBS
    • 6.6.1. Unmet Need
    • 6.6.2. Gap Analysis
    • 6.6.3. Opportunity

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Drugs in Clinical Development
  • 7.3. Product Profiles - Late-Stage Pipeline, IBS-D
    • 7.3.1. Eluxadoline
    • 7.3.2. Ibodutant (MEN-15596)
  • 7.4. Product Profiles - Late-Stage Pipeline, IBS-C
    • 7.4.1. Plecanatide
    • 7.4.2. Tenapanor (AZD1722, RDX5791)
  • 7.5. Other Drugs in Development for IBS

8. Market Outlook

  • 8.1. Japan
    • 8.1.1. Forecast
    • 8.1.2. Key Events
    • 8.1.3. Drivers and Barriers - Global Issues
    • 8.1.4. Drivers and Barriers - Japan

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed IBS Patients
    • 9.4.2. Drugs Included in Each Therapy Type
    • 9.4.3. Launch and Patent Expiry Dates
    • 9.4.4. General Pricing Assumptions
    • 9.4.5. Individual Drug Assumptions
    • 9.4.6. Generic Erosion
    • 9.4.7. Pricing of Pipeline Agents
  • 9.5. Primary Research - KOLs Interviewed for This Report
  • 9.6. Primary Research - Prescriber Survey
  • 9.7. About the Authors
    • 9.7.1. Analyst
    • 9.7.2. Therapy Area Director
    • 9.7.3. Global Head of Healthcare
  • 9.8. About GlobalData
  • 9.9. Disclaimer

List of Tables

  • Table 1: Common Symptoms of IBS
  • Table 2: Summary of the Various Diagnostic Criteria Used for the Diagnosis of IBS
  • Table 3: Treatment Guidelines for IBS
  • Table 4: Leading Prescribed Drugs for IBS by Predominant Symptoms in Japan Market, 2014†
  • Table 5: IBS Diagnosis and Treatment, Country Profile - Japan
  • Table 6: Leading Branded Treatments for IBS, 2014
  • Table 7: Product Profile - Amitiza
  • Table 8: Safety of Amitiza - Most Frequently Reported Adverse Events
  • Table 9: Amitiza SWOT Analysis, 2014
  • Table 10: Product Profile - Linzess
  • Table 11: Efficacy Responder Rates in Linzess' Two Placebo-Controlled IBS-C Trials: At Least Nine Out of 12 Weeks
  • Table 12: Efficacy Responder Rates in Linzess' Two Placebo-Controlled IBS-C Trials: At Least Six Out of 12 Weeks
  • Table 13: Safety of Linzess - Most Frequently Reported Adverse Events
  • Table 14: Linzess SWOT Analysis, 2014
  • Table 15: Product Profile - Irribow
  • Table 16: Irribow SWOT Analysis, 2014
  • Table 17: Use of Antidepressants in IBS, SWOT Analysis, 2014
  • Table 18: Summary of Other Therapeutic Classes of Pharmacologics in IBS, 2014
  • Table 19: Unmet Needs and Opportunities in IBS
  • Table 20: Drugs in Late-Stage Clinical Development for IBS, 2014
  • Table 21: Product Profile - Eluxadoline
  • Table 22: Eluxadoline SWOT Analysis, 2014
  • Table 23: Product Profile - Ibodutant
  • Table 24: Ibodutant SWOT Analysis, 2014
  • Table 25: Product Profile - Plecanatide
  • Table 26: Plecanatide SWOT Analysis, 2014
  • Table 27: Product Profile - Tenapanor
  • Table 28: Tenapanor SWOT Analysis, 2014
  • Table 29: Drugs in Early-Stage Clinical Development for IBS, 2014
  • Table 30: Sales Forecasts ($m) for IBS in Japan, 2013-2023
  • Table 31: Key Events Impacting Sales for IBS in Japan, 2013-2023
  • Table 32: Global IBS Market - Drivers and Barriers, 2013-2023
  • Table 33: IBS Market in Japan - Drivers and Barriers, 2013-2023
  • Table 34: Key Launch Dates
  • Table 35: Key Patent Expiries
  • Table 36: High-Prescribing Physicians (Non-KOLs) Surveyed, in Japan

List of Figures

  • Figure 1: Summary of Pharmacotherapies Used to Treat IBS
  • Figure 2: IBS - Phase IIb-III Pipeline, October 2014
  • Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in IBS, 2013-2023
  • Figure 4: Clinical and Commercial Positioning of Eluxadoline
  • Figure 5: Clinical and Commercial Positioning of Ibodutant
  • Figure 6: Clinical and Commercial Positioning of Plecanatide
  • Figure 7: Clinical and Commercial Positioning of Tenapanor
  • Figure 8: Sales for IBS in Japan by Therapy Type, 2013-2023
Back to Top